Inclusion criteria | Exclusion criteria |
---|---|
- Male or female aged ≥18 years; - Histologically proven adenocarcinoma of the colon; - Completed cancer staging with CT-abdomen and CT-thorax/X-thorax according to hospital’s standard of care; - Confirmed eligibility for surgery with curative intent as deemed by the hospital’s multidisciplinary board review; - Test positive for CMS4 subtype; - ≥4 properly stored pre-treatment biopsies for gene expression analysis/ELISA; - WHO performance status 0 or 1; - Adequate haematology status and organ function (defined as: normal creatinine clearance (≥60 ml/min (MDRD)), ALAT within 2.5× upper limit of normal (ULN), PT-INR < 1.5, leukocytes >1,5*10^9/L, Hb > 6.0 mmol/L, platelets >100*10^9/L); - Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests; - Provision of written informed consent. | - The presence of synchronous distant metastases; - Current hospital standard of care dictates that subject should undergo any neoadjuvant therapy; - Concurrent participation in another clinical trial using any medicinal product, or participation in such a trial in the period of three months prior to the current trial; - Women who are pregnant, plan to become pregnant or are lactating during the study or for up to 30 days after the last dose of imatinib; - Known HIV or Hepatitis B/C infection; - Known symptomatic congestive heart failure; - Co-morbidity requiring concomitant treatment with drugs that act as strong inducers of CYP3A4 or with drugs with a narrow therapeutic range influenced by imatinib. |